Logo

OCEA

Ocean Biomedical, Inc.

OCEA

Ocean Biomedical, Inc. • NASDAQ
$0.00 ▲ 0.00% (+0.00)
Market Cap $1.78 M
52w High $0.76
52w Low $0.00
Dividend Yield 0%
P/E 0
Volume 7.78K
Outstanding Shares 232.37M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q1-2025 $0 $958K ▼ $-8.24M ▼ 0% $-0.3 ▼ $-7.897M ▼
Q4-2024 $0 $1.753M ▲ $283K ▲ 0% $0.01 ▲ $716K ▲
Q3-2024 $0 $768K ▲ $-5.528M ▲ 0% $-0.2 ▲ $-5.067M ▲
Q2-2024 $0 $682K ▲ $-17.234M ▼ 0% $-0.63 ▼ $-16.719M ▼
Q1-2024 $0 $595K $12.999M 0% $0.48 $13.636M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q1-2025 $0 $1.582M ▲ $93.981M ▼ $-92.399M ▲
Q4-2024 $0 $902K ▼ $98.518M ▼ $-97.616M ▲
Q3-2024 $0 ▼ $1.132M ▼ $99.217M ▲ $-98.085M ▼
Q2-2024 $4K ▼ $1.851M ▼ $94.594M ▲ $-92.743M ▼
Q1-2024 $19K $2.946M $78.729M $-75.783M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2025 $-8.24M ▼ $-356K ▲ $0 $909K ▼ $553K ▲ $-356K ▲
Q4-2024 $283K ▲ $-2.52M ▼ $0 $2.504M ▲ $-16K ▼ $-2.52M ▼
Q3-2024 $-5.528M ▲ $-885K ▼ $0 $896K ▲ $11K ▲ $-885K ▼
Q2-2024 $-17.234M ▼ $-290K ▲ $0 $0 $-290K ▲ $-290K ▲
Q1-2024 $12.999M $-485K $0 $0 $-485K $-485K

Five-Year Company Overview

Income Statement

Income Statement Ocean Biomedical is still a pre‑revenue biotech company. It does not yet bring in sales from products, so its income statement is driven almost entirely by costs, mainly research, operations, and public company expenses. The company has been reporting losses per share, and those losses appear to have widened over time, which is typical for very early‑stage drug developers but still means the business is far from break‑even and depends on outside funding to keep going.

Balance Sheet

Balance Sheet The balance sheet looks very thin for a public company. Reported assets are small, cash is not clearly visible in the data provided, and a modest amount of debt has appeared. Equity has swung from slightly positive to negative, which signals that accumulated losses now exceed the book value of assets. In plain terms, the financial cushion is very limited, and the company’s ability to support long development timelines will rely heavily on raising new capital or forming partnerships.

Cash Flow

Cash Flow Cash flow disclosure here is minimal, but given the lack of revenue and ongoing losses, the underlying reality is almost certainly negative cash flow from operations. That means money is flowing out for research, staff, and overhead, with no offsetting inflows from product sales. With no meaningful investment flows or visible free cash generation, the business appears dependent on financing activities—issuing shares, taking on debt, or securing upfront payments from partners—to fund its pipeline.

Competitive Edge

Competitive Edge Ocean Biomedical is attempting to carve out a niche by focusing on novel biological targets in cancer, fibrosis, and infectious disease rather than crowded, “me‑too” areas. Its strengths are its relationships with leading academic institutions, a growing patent portfolio around unique targets like CHI3L1 and Chit1, and a flexible in‑licensing model that taps external research. However, it is still very early stage, has no approved products, and operates in a field dominated by much larger, better‑funded pharma and biotech companies. Its recent move into energy and digital assets adds strategic complexity and could dilute focus from its core drug programs, which is something observers will likely watch closely.

Innovation and R&D

Innovation and R&D Innovation is the core of the Ocean Biomedical story. The company is building platforms around new disease drivers—CHI3L1 in oncology, Chit1 in fibrosis, and PfGARP in malaria—using antibodies, small molecules, and potentially mRNA technologies. These are ambitious, first‑in‑class style approaches that could be very impactful if they work, particularly in cancer and malaria where unmet need is high. The R&D strategy leans on in‑licensed university science, which can be efficient but also means strong execution is needed to move from promising lab data to human trials. Most programs are still preclinical or very early, so scientific and regulatory risk remains high, and the value of the pipeline will hinge on upcoming trial starts and early safety and efficacy readouts.

Summary

Overall, Ocean Biomedical is a very early‑stage, science‑driven biotech with an interesting and differentiated research focus but a fragile financial base. It has no product revenue, ongoing losses, and a balance sheet that offers little room for prolonged setbacks, making continued access to capital critical. On the positive side, it holds novel targets, patent protection, and high‑impact disease areas that, if successfully developed, could be meaningful medically and commercially. On the risk side, it faces the usual high failure rates of drug development, funding and listing‑compliance pressures, and added execution risk from branching into non‑core areas like energy and digital assets. The future path will largely be determined by its ability to start and progress clinical trials, secure partnerships, and stabilize its financial position.